Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PK, safety, and tolerability of VX-121/tezacaftor/deutivacaftor in children with cystic fibrosis aged 1–11 years
2021-005930-40Phase 3Active
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of vanzacaftor + tezacaftor + deutivacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Primary endpoint - Part B (Cohort B1). Started Sep 2022; status: active.
02
Drugs
vanzacaftor + tezacaftor + deutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2021-005930-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005930-40.